The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.
The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.
复制标题
DOI：
10.2217/fon-2020-0118
复制
发表时间：
2020-05
期刊：
影响因子：
3.3
通讯作者：
Jin Liang;Dedian Chen;Liyao Chen;X. She;Hushan Zhang;Yanbin Xiao
中科院分区：
文献类型：
--
作者：
Jin Liang;Dedian Chen;Liyao Chen;X. She;Hushan Zhang;Yanbin Xiao
肉瘤是一种罕见的异质性间质恶性肿瘤。总共25-50%以最初治疗目的治疗的患者将发展为复发和转移性疾病。在复发和转移的情况下，化疗的效果是有限的；因此，迫切需要更有效的治疗方法。PD-1/PD-L1作为T细胞活化的制动器，通过改变免疫监视状态在肿瘤的进展中起着至关重要的作用。最近，PD-1/PD-L1抑制剂在治疗几种实体肿瘤方面取得了一些成功，例如非小细胞肺癌和黑色素瘤。近年来，基于PD-1/PD-L1的肉瘤免疫治疗策略也得到了探索。与其他癌症一样，主要的挑战是确定生物标志物以预测免疫治疗的反应，优化患者的益处和最小化副作用。因此，我们在本综述中重点关注免疫疗法治疗肉瘤的潜在生物标志物。
Sarcomas are rare and heterogeneous malignant tumors of mesenchymal origin. A total of 25-50% of patients treated with initial curative intent will develop as recurrent and metastatic disease. In the recurrent and metastatic setting, effect of chemotherapy is limited; therefore, more effective therapies are urgently desired. As a brake for activation of T cell, PD-1/PD-L1 plays a crucial role in the progression of tumor by altering status of immune surveillance. Some success has been acquired recently in the use of PD-1/PD-L1 inhibitors for the treatment of several solid tumors, for examples, non-small-cell lung cancer and melanoma. Immunotherapeutic strategies based on PD-1/PD-L1 for sarcomas have also been explored these years. As in other cancers, major challenges are identification of biomarkers to predict response for immunotherapy, optimization of patient's benefit and minimization of side effects. Therefore, we focused on potential biomarkers of immunotherapy for treatment of sarcomas in this review.